NASDAQ:AKAO Achaogen (AKAO) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free AKAO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.11▼$0.1152-Week Range N/AVolumeN/AAverage Volume3.34 million shsMarket Capitalization$7.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Achaogen alerts: Email Address Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Achaogen Stock (NASDAQ:AKAO)Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.Read More Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up AKAO Stock News HeadlinesFebruary 21, 2024 | benzinga.comRavi Viswanathan's Net WorthDecember 28, 2023 | bbc.comCOP28: Climate mums make themselves heard in halls of powerMarch 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.October 25, 2023 | investing.comAKAOQ Historical DataJuly 28, 2022 | finance.yahoo.comSepterna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines - Yahoo FinanceJune 13, 2022 | nj.comAn N.J. medical expert warns of the rise of superbugs | Opinion - NJ.comApril 28, 2022 | streetinsider.comFlare Therapeutics Appoints Adrian Jubb as Chief Medical Officer - StreetInsider.comApril 26, 2022 | finance.yahoo.comFlare Therapeutics Appoints Adrian Jubb as Chief Medical Officer - Yahoo FinanceMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.April 13, 2022 | law360.comCipla Calls Achaogen Claims Over Lost Ch. 11 Sales 'Weak' - Law360April 13, 2022 | ft.comGreater access to antibiotics is essential for curbing drug resistance - Financial TimesApril 4, 2022 | bizjournals.comLife sciences VC 5AM Ventures adds 2 new funds totaling $750M - San Francisco Business Times - The Business JournalsMarch 19, 2022 | thetimes.co.ukShortage of new antibiotics stokes fears of a 'silent pandemic' - The TimesFebruary 14, 2022 | forbes.comForever In Love And In Love With Forever: Introducing The World's First True Longevity Couple - ForbesFebruary 2, 2022 | globenewswire.comGlobal Urinary Tract Infection Therapeutics Market Size Will Touch USD 11652 Million Mark by 2027, at a 4.56% CAGR - GlobeNewswireJanuary 27, 2022 | finance.yahoo.comApplied Molecular Transport Announces Board Appointments - Yahoo FinanceNovember 25, 2021 | fortune.comTo avoid the superbug pandemic, we must fix the business model for new antibiotics - FortuneNovember 4, 2021 | businesswire.comGlobal Antibiotic Resistance Markets, 2019-2020 & 2021-2027 - Focus on Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies - ResearchAndMarkets.com - Business WireOctober 8, 2021 | law360.comThe Top In-House Hires Of September - Law360September 27, 2021 | businesswire.comGlobal $13.8 Billion Antimicrobial Resistance Market, 2027 | Opportunity Breakdown by Disease, Pathogen, Drug Class, End-user and Region - ResearchAndMarkets.com - Business WireSeptember 16, 2021 | prnewswire.comGlobal Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021 - PRNewswireSeptember 15, 2021 | seekingalpha.comContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market - Seeking AlphaSeptember 9, 2021 | law360.comCRISPR Biotech Co. Mammoth Hires Sangamo Atty As GC - Law360August 26, 2021 | bizjournals.comBiotech Dice led by Kevin Judice rolls toward $100M IPO - San Francisco Business Times - San Francisco Business TimesAugust 9, 2021 | businesswire.comCarbapenem-Resistant Enterobacteriaceae Infection Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com - Business WireSee More Headlines Receive AKAO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achaogen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2018Today3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AKAO CUSIPN/A CIK1301501 Webwww.achaogen.com Phone650-800-3636FaxN/AEmployees206Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-186,510,000.00 Net Margins-2,136.94% Pretax MarginN/A Return on Equity-357.49% Return on Assets-127.68% Debt Debt-to-Equity Ratio1.00 Current Ratio0.78 Quick Ratio0.77 Sales & Book Value Annual Sales$8.73 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / BookN/AMiscellaneous Outstanding Shares63,880,000Free FloatN/AMarket Cap$7.03 million OptionableOptionable Beta0.78 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Blake Wise (Age 48)CEO & Director Mr. Gary Loeb (Age 49)Gen. Counsel, Corp. Sec. & Chief Compliance Officer Ms. Zeryn Sarpangal (Age 39)CFO and Principal Financial & Accounting Officer Ms. Elizabeth Bhatt (Age 50)Chief Bus. Officer & COO Ms. Jeannie LloydsVP of SalesKey CompetitorsGT BiopharmaNASDAQ:GTBPGraybug VisionNASDAQ:GRAYShuttle PharmaceuticalsNASDAQ:SHPHVaccinexNASDAQ:VCNXBright Minds BiosciencesNASDAQ:DRUGView All Competitors AKAO Stock Analysis - Frequently Asked Questions How were Achaogen's earnings last quarter? Achaogen Inc (NASDAQ:AKAO) posted its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.19. The biopharmaceutical company had revenue of $2.56 million for the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative trailing twelve-month return on equity of 357.49% and a negative net margin of 2,136.94%. What other stocks do shareholders of Achaogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), First Data (FDC), Ciena (CIEN), Cypress Semiconductor (CY) and Synergy Pharmaceuticals (SGYP). This page (NASDAQ:AKAO) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achaogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.